Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.44 |
| ▸ | FNTB | P49356 | 3/20 | 0.44 |
| ▸ | FEN1 | P39748 | 3/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829208 | 0.92 | FNTA (0.46) | FNTAFNTBFEN1ALOX5APP2RX3 | |
| SCHEMBL829149 | 0.87 | SCN9A (0.49) | FNTAFNTBFEN1ALOX5APP2RX3 | |
| SCHEMBL832178 | 0.77 | MAPK8 (0.39) | KRAS | |
| SCHEMBL831838 | 0.75 | PDE4A (0.42) | ALDH1A1LMNAGAAKMT2ANPSR1 | |
| SCHEMBL829937 | 0.74 | SCN9A (0.38) | SCN9AKRAS | |
| SCHEMBL831263 | 0.74 | MKNK2 (0.46) | ALDH1A1NPSR1P2RX3CYP2C9 | |
| SCHEMBL388313 | 0.74 | PCSK9 (0.37) | TP53 | |
| SCHEMBL832909 | 0.67 | PDE4A (0.43) | LMNAGAAKMT2ANPSR1CYP2C9 | |
| SCHEMBL7366249 | 0.67 | CHEK2 (0.58) | FEN1ALOX5APNPSR1SCN9ACHEK2 | |
| SCHEMBL829209 | 0.67 | ACP1 (0.34) | FNTAFNTBFEN1ALOX5APTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614229-B2 | Substituted indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2013-12-24 | — | — | US | disclosed |
| EP-2197842-B1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2408761-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | Schering Corporation (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| EP-2197842-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | FNTA 3144/4885FNTB 4719/4885FEN1 2381/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | FNTA 2632/4885FNTB 4387/4885FEN1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.